GSK’s RSV Vaccine Moves Closer to China Approval
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year
False
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 7, 2026
2 min read
Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
September 30, 2026
2 min read
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
September 28, 2026
2 min read
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
False
Affiliations:
Specialties:
Areas of Expertise: